Gilead Working 24/7 To Fix Manufacturing Problems In HIV “Complete Response” Letters
This article was originally published in The Pink Sheet Daily
In its first quarter earnings call, Gilead says it’s been working around the clock to address manufacturing issues that blocked FDA approval of two individual drugs in the approved Stribild HIV combination pill, problems that also affect other marketed drugs. But rising star HCV drug sofosbuvir won’t be affected, company says.
You may also be interested in...
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.